Description: AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
Home Page: www.aimimmuno.com
AIM Technical Analysis
2117 SW Highway 484
Ocala,
FL
34473
United States
Phone:
352 448 7797
Officers
| Name | Title |
|---|---|
| Mr. Thomas K. Equels Esq., J.D., M.S. | Exec. Vice Chairman, CEO & Pres |
| Mr. Peter W. Rodino III, Esq., J.D. | COO, Exec. Director of Gov.al Relations, Gen. Counsel & Sec. |
| Mr. Robert Dickey IV, M.B.A. | Chief Financial Officer |
| Dr. David R. Strayer M.D. | Chief Scientific Officer & Medical Director |
| Ann Marie E. Coverly | Director of Admin. & HR and Deputy Investor Relations Coordinator |
| Dr. Carol A. Smith | Chief Manufacturing Officer & Deputy Chief Scientific Officer |
| Jodie Pelz | Controller |
| Dr. Ralph Christopher Cavalli Ph.D. | VP of QC & Manufacturing |
Exchange: NYSE MKT
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Aerospace & Defense |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4066 |
| Price-to-Sales TTM: | 123.4825 |
| IPO Date: | 1996-07-12 |
| Fiscal Year End: | January |
| Full Time Employees: | 21 |